Company / Cost of Revenue
Amphstar Pharmaceuticals, Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$363.8M
FY2025
5-year range
$238.0M / $363.8M
FY2021-FY2025
Trend
+1.6%
vs FY2024
Sector context
#27 of 85
Health Care
What the data says
At $364M, Amphstar Pharmaceuticals, Inc.'s cost of revenue ranks #59 of 85 in the Health Care sector. Cost of Revenue has increased for 8 consecutive years, from $150M in FY2017 to $364M in FY2025.
Based on SEC 10-K filings.
$364M in FY2025 with a 5-year CAGR of +12.0%.
Increased from $293M to $364M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +13.3%
- 5-Year CAGR
- +12.0%
- 10-Year CAGR
- -
Sector benchmark
#59 of 85 in Health CareTop 68% of 85This company $363.8M Sector average $2.0B
▼
-81.7% below sector average
Key checks
Key Insights
- Amphstar Pharmaceuticals, Inc.'s cost of revenue has grown for 8 consecutive years.
- 5-year CAGR of +12.0%, indicating consistent growth.
- In FY2025, cost of revenue increased 1.6% year-over-year.
- Ranks #27 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $363.8M | +1.6% |
| FY2024 | $358.1M | +22.1% |
| FY2023 | $293.3M | +17.3% |
| FY2022 | $250.1M | +5.1% |
| FY2021 | $238.0M | +15.3% |
| FY2020 | $206.5M | +8.4% |
| FY2019 | $190.4M | +1.5% |
| FY2018 | $187.7M | +25.4% |
| FY2017 | $149.7M | -0.9% |
| FY2016 | $151.0M | -13.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026